Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA.
Cell. 2024 Oct 3;187(20):5500-5529. doi: 10.1016/j.cell.2024.07.054. Epub 2024 Sep 25.
Long COVID, a type of post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (PASC) defined by medically unexplained symptoms following infection with SARS-CoV-2, is a newly recognized infection-associated chronic condition that causes disability in some people. Substantial progress has been made in defining its epidemiology, biology, and pathophysiology. However, there is no cure for the tens of millions of people believed to be experiencing long COVID, and industry engagement in developing therapeutics has been limited. Here, we review the current state of knowledge regarding the biology and pathophysiology of long COVID, focusing on how the proposed mechanisms explain the physiology of the syndrome and how they provide a rationale for the implementation of a broad experimental medicine and clinical trials agenda. Progress toward preventing and curing long COVID and other infection-associated chronic conditions will require deep and sustained investment by funders and industry.
长新冠,一种由严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)(PASC)引起的急性后后遗症,定义为感染 SARS-CoV-2 后出现的无法用医学解释的症状,是一种新发现的与感染相关的慢性疾病,在某些人中导致残疾。在定义其流行病学、生物学和病理生理学方面已经取得了重大进展。然而,对于数千万被认为患有长新冠的人来说,目前还没有治愈方法,而且行业在开发治疗方法方面的参与度有限。在这里,我们回顾了长新冠的生物学和病理生理学的现有知识,重点关注所提出的机制如何解释该综合征的生理学,以及它们如何为实施广泛的实验医学和临床试验议程提供依据。要预防和治疗长新冠和其他与感染相关的慢性疾病,需要资助者和行业进行深入和持续的投资。